Search
Triazavirin
go.drugbank.com/drugs/DB15622Investigational[L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625]
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Bempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigationalHigh levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality ...
Elamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigationalElamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction. Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochond...
Patiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalwell-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as … methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage. … [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296]
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, ...